To deepen understanding of efforts to consider addiction a "brain disease," we review critical appraisals of the disease model in conjunction with responses from in-depth semistructured stakeholder interviews with (1) patients in treatment for addiction and (2) addiction scientists. Sixty-three patients (from five alcohol and/or nicotine treatment centers in the Midwest) and 20 addiction scientists (representing genetic, molecular, behavioral, and epidemiologic research) were asked to describe their understanding of addiction, including whether they considered addiction to be a disease. To examine the NIDA brain disease paradigm, our approach includes a review of current criticism from the literature, enhanced by the voices of key stakeholders. Many argue that framing addiction as a disease will enhance therapeutic outcomes and allay moral stigma. We conclude that it is not necessary, and may be harmful, to frame addiction as a disease.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969751 | PMC |
http://dx.doi.org/10.1080/21507740.2013.796328 | DOI Listing |
Gastro Hep Adv
September 2024
Division of Gastroenterology and Hepatology, Johns Hopkins University, Baltimore, Maryland.
Actas Esp Psiquiatr
January 2025
Psychiatry Department, Hospital Clínico Universitario de Valencia, 46010 Valencia, Spain; Research Group on Psychiatry and Neurodegenerative Diseases, INCLIVA-Instituto de Investigación Sanitaria, 28009 Valencia, Spain; CIBERSAM-Centro de Investigación Biomédica en Red de Salud Mental, 28029 Madrid, Spain; Medicine Department, Faculty of Medicine, University of Valencia, 46010 Valencia, Spain.
Background: Efforts to improve psychiatry training must incorporate residents' assessment of their training. This study sought to collect the opinion of residents about the program that has been in force in Spain since 2008, until the current transition to a new plan.
Methods: The authors conducted an online survey of psychiatry residents in Spain, asking about their formative and working conditions.
Genes Brain Behav
February 2025
Laboratory of Addiction Genetics, Department of Pharmaceutical Sciences and Center for Drug Discovery, Northeastern University, Boston, Massachusetts, USA.
Opioid use disorder is heritable, yet its genetic etiology is largely unknown. C57BL/6J and C57BL/6NJ mouse substrains exhibit phenotypic diversity in the context of limited genetic diversity which together can facilitate genetic discovery. Here, we found C57BL/6NJ mice were less sensitive to oxycodone (OXY)-induced locomotor activation versus C57BL/6J mice in a conditioned place preference paradigm.
View Article and Find Full Text PDFSchizophr Bull
January 2025
Orygen, Parkville, Victoria 3052, Australia.
Background: Although attention deficit hyperactivity disorder (ADHD) is known to be common in psychotic disorders, reported prevalence rates vary widely, with limited understanding of how different factors (eg, assessment methods, geographical region) may be associated with this variation. The aim was to conduct a systematic review and meta-analysis to determine the prevalence of ADHD in psychotic disorders and factors associated with the variability in reported rates.
Study Design: Searches were conducted in MEDLINE, Embase, PsycINFO, CINAHL, and Scopus in May 2023.
J Prev Alzheimers Dis
January 2025
Division of Neurogeriatrics, Department of Neurobiology Care Sciences and Society; Karolinska Institutet; Sweden; BioClinicum J9:20, Akademiska stråket, 171 64 Solna, Sweden.
Introduction: Informal care estimates for use in health-economic models are lacking. We aimed to estimate the association between informal care time and dementia symptoms across Europe.
Methods: A secondary analysis was performed on 13,529 observations in 5,369 persons from 9 European pooled cohort or trial studies in community-dwelling persons with dementia.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!